Should you buy Amgen stock now?
Yes, the technical signal for Amgen is currently BUY. Amgen trades at $402.46 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 10.012 with rising momentum (signal: 7.969); RSI is at 72.5 (overbought), suggesting the price may have risen too quickly; the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $357.03 is 11.3% below the current price. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Amgen stock?
The average analyst price target for Amgen is $357.03. The current price is $402.46, which gives a downside of 11.3%. Based on this, the stock is considered overvalued. The fair value range (±10% of the price target) is between $321.33 and $392.73.
Is Amgen a dividend stock?
Yes, Amgen is a dividend stock with a dividend yield of 2.55%. The latest dividend was $2.52 per share. The latest ex-dividend date (traded without the dividend) was 8/21/2026. The payout ratio is 44.4%, which is considered sustainable. The next dividend payment is scheduled for 9/11/2026.
When does Amgen pay a dividend in 2026?
Amgen pays its next dividend on 9/11/2026. The latest dividend was $2.52 per share with an ex-dividend date of 8/21/2026. The dividend yield is 2.55%. The payout ratio of 44.4% points to a sustainable dividend with room to grow.
What is the risk of Amgen stock?
Amgen is rated as a stock with moderately low risk. the annual standard deviation is 27.4%, which classifies the stock as moderately low risk. In addition, an RSI of 72.5 signals overbought (elevated risk of a pullback).
Is Amgen overvalued?
Yes, Amgen is considered overvalued based on the analyst price target (11.3% above the price target). Amgen has the following valuation ratios: a P/E ratio of 27.2 (moderately to highly valued), a P/S ratio of 5.7, a P/B ratio of 22.6. The analyst price target suggests that the stock is overvalued by 11.3%.
Is Amgen overbought?
Yes, Amgen is overbought with an RSI of 72.5 (above 70). The technical indicators show: RSI is at 72.5 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, the price is 7.5% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Amgen earnings report?
The date of the next earnings report for Amgen has not been published yet. Check the company's investor calendar for updates.
Is Amgen shorted?
Yes, Amgen is shorted with 2.4% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Amgen stock?
No, insiders are not buying Amgen shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 2,733,302 $ sold. Active sellers include Santos Esteban, REESE DAVID M, Miller Derek and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Amgen a good stock?
Based on our total score, Amgen is rated as a good stock with a total score of 70 out of 100. The stock scores above average on value, quality and momentum – it is among the top 30% in our database. The score is made up of Value: 33/100, Quality: 89/100, Momentum: 88/100. In addition: the price target is 11.3% below the current price; a dividend of 2.55%; technical signal: Strong Buy. Whether Amgen is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Amgen stock?
The outlook for Amgen based on current data: the average analyst price target is $357.03 (-11.3%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 27.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Amgen stock rising?
Amgen is rising right now. The technical indicators show: the price is 7.5% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Amgen go?
The average analyst price target for Amgen is $357.03, which is 11.3% below the current price of $402.46. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Amgen fall?
We lack enough history to give a specific floor for Amgen. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Amgen do?
Amgen laver og sælger medicin globalt. De opdager, udvikler og producerer behandlinger til folk med alvorlige sygdomme, især inden for betændelse, kræft, hjerte-kar-lidelser og knoglesundhed. Amgen tjener især penge på salget af store lægemidler.
De er kendt for produkter som... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Amgen as an investment.
Did Amgen raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Amgen. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Amgen making money or losing money?
Yes, Amgen is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 21.0% — which is excellent. The operating margin (profit before interest and taxes) is 33.8%. At a P/E ratio of 27.2, you currently pay 27.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Amgen go bankrupt?
The bankruptcy risk of Amgen is rated as elevated. Altman Z2 (a model for assessing financial distress) is 0.86 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 1,463% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Amgen have a lot of debt?
Yes, Amgen has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,463%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
